Q-omics provides the consensus-scored CD151 profile across patient tissues and cancer cell-line models. CD151 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, CD151 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, CD151 protein abundance shows 19,843 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight HNSC, KIRC, and BRCA as cancer lineages where CD151 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CD151 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CD151 survival associations across molecular data types. CD151 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CD151 RNA expression–survival associations across cancer types. High CD151 expression shows unfavorable associations in HNSC, LUSC, ACC, LGG, UCS and LIHC. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for CD151 RNA expression.
This table summarizes CD151 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CD151. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CD151 shows lower tumor expression in LUSC and higher tumor expression in KIRC, HNSC, KIRP, THCA and LIHC. The KIRC box plot shows higher CD151 RNA expression in tumor versus normal tissue (log2 FC = +1.113, t-test p < 0.001).
This table shows molecular features associated with CD151 in patient tissues and cancer cell lines. In patient samples, CD151 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, CD151 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LUNG_SCLC.
